The Translational Breast Cancer Research Consortium was well represented at the 2013 ASCO Meeting.  Presentations included:

TBCRC 002: A phase II, randomized, open label trial of pre-operative letrozole vs. letrozole (LET) in combination with bevacizumab (BEV) in post-menopausal women with newly diagnosed stage II/III breast cancer; Abstract # 527

Prognostic impact of 21-gene Recurrence Score in patients presenting with Stage IV breast cancer (BC) (TBCRC 013); Abstract # 507

TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple negative breast cancer (TNBC) central nervous system (CNS) metastases (mets); Abstract # 515

TBCRC 019: An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab (TIG) in patients with metastatic triple negative breast cancer (TNBC); Abstract # 1052